The Global Health Body Issues Warning Over Critical Lack of Obesity Medications
Under one in 10 individuals that would benefit from weight-loss injections like Wegovy are able to get them, states the WHO as it releases its inaugural guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just availability to this class of drugs.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a chronic disease that can be managed with holistic and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are major hurdles to broad availability to the jabs that can help people shift considerable weight, says the organization.
Weight-Loss Drug Scarcity
Even under the current most favorable scenario, the production of these medications might only reach approximately 100 million people – under 10% of those who need them, according to the WHO.
The advice urges governments and firms to widen availability, via approaches like voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
How Obesity Injections Operate
GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and boost feelings of fullness so people reduce food intake.
Patients usually start to lose weight after several weeks of starting on the regular doses.
Research indicates people may see weight return within a year of stopping the drug, as their usual appetite come back.
To be above a healthy weight elevates your chance for contracting health problems, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight affects individuals in all nations and was responsible for millions of deaths worldwide in 2024, according to the WHO.
